-
Innovation Ranking
NewInnovation Ranking – Atossa Therapeutics Inc
Atossa Therapeutics Inc (Atossa), formerly Atossa Genetics Inc is a clinical-stage biopharmaceutical company. It develops proprietary therapeutics and delivery methods for breast cancer and other breast conditions. The company’s pipeline pharmaceutical programs include endoxifen, an active metabolite of tamoxifen, used for the treatment of breast density and other breast health conditions. Atossa is developing patented microcatheter technology to deliver fulvestrant as a potential treatment of ductal carcinoma through the nipple to site of early breast cancer. The company also uses...
-
Product Insights
NewNet Present Value Model: Atossa Therapeutics Inc’s Endoxifen
Empower your strategies with our Net Present Value Model: Atossa Therapeutics Inc's Endoxifen report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: UroGen Pharma Ltd’s Vesigel
Empower your strategies with our Net Present Value Model: UroGen Pharma Ltd's Vesigel report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Endoxifen in Ductal Carcinoma In Situ
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Endoxifen in Ductal Carcinoma In Situ report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Endoxifen in Ductal Carcinoma In Situ Drug Details: Endoxifen is...
-
Product Insights
Ductal Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ductal Carcinoma - Drugs In Development, 2023’, provides an overview of the Ductal Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mammary Ductal Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Mammary Ductal Carcinoma - Drugs In Development, 2023’, provides an overview of the Mammary Ductal Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mammary Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Ductal Carcinoma In Situ – Drugs In Development, 2023
Global Markets Direct’s, ‘Ductal Carcinoma In Situ - Drugs In Development, 2023’, provides an overview of the Ductal Carcinoma In Situ pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ductal Carcinoma In Situ, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Endoxifen in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Endoxifen in Ovarian Cancer Drug Details: Endoxifen is under development for the treatment of HER2...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TQB-3234 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TQB-3234 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TQB-3234 in Colorectal Cancer Drug Details: TQB-3234 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosciclopirox in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosciclopirox in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fosciclopirox in Relapsed Acute Myeloid Leukemia Drug Details: CPX-POM (Ciclopirox prodrug)...